Indivior Inc. v. Dr. Reddy's Laboratories, S.A.
930 F.3d 1325
Fed. Cir.2019Background
- Indivior (and licensor Aquestive) owns patents covering sublingual pharmaceutical films (notably U.S. Patents '514, '497, '150, and '832) and markets Suboxone® film. Multiple ANDA filers (DRL, Watson, Teva, Alvogen) were sued for infringement.
- The core technical problem: achieving drug-content uniformity in cast films; claimed solutions emphasize matrix viscosity and controlled drying (bottom drying, microwave, or controlled zone drying) to avoid a surface "ripple effect" caused by conventional top convection drying.
- Claim 62 of the '514 patent requires a cast film from a flowable matrix with a viscosity that "aids" uniformity and that is "capable of being dried without loss of substantial uniformity." The '497 patent claims similar drying limitations. The '150 patent claims a polymer composition (PEO + hydrophilic cellulosic polymer) with specified proportions.
- District courts held multiple bench trials: found Watson infringed the '514 patent but denied indefiniteness; found DRL and Alvogen did not infringe the '514 patent under the court's narrower claim construction excluding sole use of conventional top convection air drying; found DRL did not infringe the '150 patent (doctrine of equivalents rejected by disclosure-dedication); courts found asserted claims not shown obvious; separate IPRs led to cancellation of some '832 claims.
- On appeal the Federal Circuit affirmed in part, vacated the district-court invalidity judgment for certain '832 claims as moot, and upheld: the claim construction that the specification disclaims sole conventional top air drying; noninfringement findings for DRL and Alvogen; infringement for Watson; denial of Rule 59 relief to Watson; rejection of indefiniteness challenge to the '514 claims; and upheld nonobviousness of the '514 and '150 claims and the written-description-based priority for the '150 patent.
Issues
| Issue | Indivior's Argument (Plaintiff) | Defendants' Argument | Held |
|---|---|---|---|
| Proper construction of the '514 "drying" limitation | Claim language should get its plain meaning; specification shouldn't disclaim conventional top drying; zone drying embodiments remain covered | Specification disclaims conventional top convection air drying; claims exclude solely top-air drying | Court (Fed. Cir.): specification repeatedly disfavors conventional top-air drying; claim construed to exclude solely employing conventional top convection air drying; affirmed |
| Infringement by DRL / Alvogen (under constructed drying term) | Their processes include sufficient controlled/balanced bottom drying or zone drying to meet the limitation | Their dryers use heat solely from above; any bottom heating is incidental | Noninfringement affirmed for DRL and Alvogen (no clear error in district court factual findings) |
| Watson: Rule 59 relief after ANDA amendment and infringement judgment | Relief warranted because litigation outcomes should not depend on which defendant requested construction; amended process removes bottom heating | Watson waived claim-construction argument by not requesting it earlier; district court discretion to deny Rule 59; Watson may litigate amended process separately | Denial of Rule 59 affirmed (no abuse of discretion); infringement judgment for Watson on original ANDA also affirmed (viscosity limitation met) |
| Indefiniteness of '514 claim wording ("flowable cast film") | Language is impossible/contradictory: a cast film cannot be simultaneously "flowable" | Read in view of the specification: term refers to the flowable matrix during manufacture that is then dried; not indefinite | Claim not indefinite; reasonable certainty provided by specification; affirmed |
| Obviousness of '514 (and '497) patents over prior art (Schmidt, Chen, Strobush) | Prior art taught relevant coating/drying techniques and would have motivated combination to achieve uniform films; obvious | Prior art did not teach post-drying drug-content uniformity or the claimed controlled drying; field was nascent; no reasonable expectation of success; secondary considerations support nonobviousness | Affirmed nonobviousness: district court factual findings were not clearly erroneous; insufficient clear-and-convincing evidence of obviousness |
| Doctrine of equivalents vs disclosure-dedication for '150 patent (PVP vs HCP) | DRL's use of PVP still equivalent to claimed HCP | Specification expressly discloses PVP as an alternative (unclaimed) => dedication to public; cannot recapture by equivalents | Disclosure-dedication applies; DRL's use of PVP does not infringe under doctrine of equivalents; affirmed |
| Priority / written-description for '150 patent (entitlement to '902 filing date) | '902 provisional supplies adequate written description for claimed polymer component (>=75% PEO, >=60% L-PEO, up to 25% HCP) | '902 does not show possession of the specific claimed polymer proportions; examples lack exact claimed combination; written description inadequate | Federal Circuit affirmed district court: '902 provides adequate support; '150 entitled to the earlier priority; nonobviousness affirmed |
Key Cases Cited
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir.) (specification is primary guide to claim meaning)
- SciMed Life Sys., Inc. v. Advanced Cardiovascular Sys., Inc., 242 F.3d 1337 (Fed. Cir.) (clear disclaimer in specification limits claim scope)
- Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898 (U.S. 2014) (indefiniteness standard: reasonable certainty)
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (U.S. 2007) (obviousness: flexible, common-sense analysis)
- Gemtron Corp. v. Saint-Gobain Corp., 572 F.3d 1371 (Fed. Cir.) (claim terms can describe a property at a particular time, e.g., during assembly)
- Johnson & Johnston Assocs., Inc. v. R.E. Serv. Co., 285 F.3d 1046 (Fed. Cir.) (disclosure-dedication rule bars recapture by equivalents)
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir.) (written-description requirement standard)
- Graham v. John Deere Co., 383 U.S. 1 (U.S. 1966) (Graham factors for obviousness)
- Microsoft Corp. v. i4i Ltd. P'ship, 564 U.S. 91 (U.S. 2011) (burden: clear and convincing evidence to overcome patent validity presumption)